Efficacy and Safety of Androgel in the Treatment of Hypogonadal and Low Testosterone Men With Type 2 Diabetes
NCT ID: NCT00141492
Last Updated: 2015-01-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
INTERVENTIONAL
2004-10-31
2007-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism
NCT00467987
Effect of Androgel on Type 2 Diabetic Males With Hypogonadism
NCT00350701
Effect of Testosterone Gel Replacement on Fat Mass in Males With Low Testosterone Levels and Diabetes
NCT00440440
Effect of Testosterone Replacement on Insulin Resistance
NCT00487734
Effects of Testosterone Gel on Carbohydrate and Lipid Metabolism In Elderly Obese Men
NCT00365794
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Androgel (testosterone gel)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Males
3. Between 30-80 years old
4. Have type 2 diabetes
5. Diagnoses of hypogonadism or low testosterone
Exclusion Criteria
2. Use of testosterone therapy within the last 6 months
3. Male breast cancer
4. History of prostate cancer
5. History of clinically significant sleep apnea
30 Years
80 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Solvay Pharmaceuticals
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Director Solvay
Role: STUDY_DIRECTOR
Solvay Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site 58
Birmingham, Alabama, United States
Site 67
Calera, Alabama, United States
Site 54
Mobile, Alabama, United States
Site 16
Phoenix, Arizona, United States
Site 35
Anaheim, California, United States
Site 23
Concord, California, United States
Site 55
La Jolla, California, United States
Site 8
Los Gatos, California, United States
Site 12
Mission Viejo, California, United States
Site 1
Torrance, California, United States
Site 25
Glastonbury, Connecticut, United States
Site 13
Fort Lauderdale, Florida, United States
Site 43
Jacksonville, Florida, United States
Site 33
Ocala, Florida, United States
Site 27
Tampa, Florida, United States
Site 21
West Palm Beach, Florida, United States
Site 7
Atlanta, Georgia, United States
Site 26
Columbus, Georgia, United States
Site 29
Boise, Idaho, United States
Site 45
Idaho Falls, Idaho, United States
Site 51
Chicago, Illinois, United States
Site 32
Des Moines, Iowa, United States
Site 5
Baton Rouge, Louisiana, United States
Site 70
Baltimore, Maryland, United States
Site 9
Springfield, Massachusetts, United States
Site 48
Watertown, Massachusetts, United States
Site 19
Detroit, Michigan, United States
Site 61
Livonia, Michigan, United States
Site 40
Tupelo, Mississippi, United States
Site 65
Chesterfield, Missouri, United States
Site 15
Kansas City, Missouri, United States
Site 41
Omaha, Nebraska, United States
Site 34
Las Vegas, Nevada, United States
Site 24
Jersey City, New Jersey, United States
Site 49
Buffalo, New York, United States
Site 71
New York, New York, United States
Site 44
Fayetteville, North Carolina, United States
Site 28
Morehead City, North Carolina, United States
Site 60
Morehead City, North Carolina, United States
Site 31
Portland, Oregon, United States
Site 3
Portland, Oregon, United States
Site 68
Altoona, Pennsylvania, United States
Site 4
Bala-Cynwyd, Pennsylvania, United States
Site 64
Carlisle, Pennsylvania, United States
Site 38
Lansdale, Pennsylvania, United States
Site 46
Shippensburg, Pennsylvania, United States
Site 14
Greer, South Carolina, United States
Site 20
Arlington, Texas, United States
Site 11
Dallas, Texas, United States
Site 10
Houston, Texas, United States
Site 18
Houston, Texas, United States
Site 2
Houston, Texas, United States
Site 36
Houston, Texas, United States
Site 39
Houston, Texas, United States
Site 42
Houston, Texas, United States
Site 47
Houston, Texas, United States
Site 53
Houston, Texas, United States
Site 62
Houston, Texas, United States
Site 63
Houston, Texas, United States
Site 69
Houston, Texas, United States
Site 6
Humble, Texas, United States
Site 30
La Porte, Texas, United States
Site 66
Midland, Texas, United States
Site 37
San Antonio, Texas, United States
Site 56
Sugarland, Texas, United States
Site 57
Sugarland, Texas, United States
Site 52
Ogden, Utah, United States
Site 17
Salt Lake City, Utah, United States
Site 22
Salem, Virginia, United States
Site 50
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
S176.2.101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.